|01/03/19||GBT Announces New Employment Inducement Grants|
|SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on January 1, 2019, the compensation committee of the Company’s board of directors granted three new employees options to purchase an aggregate of 6,000 shares of the Company’s common stock with a per share exercise price of $41.05 and restricted stock units for an aggregate of 3,950 shares of the Company’s common stock. All of the above-descri... |
|01/02/19||GBT to Present at the 37th Annual J.P. Morgan Healthcare Conference|
|SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019, at 11:30 a.m. Pacific Time.
The presentation and Q&A session will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for replay for one month following the event.
|12/21/18||GBT Appoints Dawn Svoronos to Board of Directors|
|SOUTH SAN FRANCISCO, Calif., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Dawn Svoronos to the company’s board of directors. Ms. Svoronos has more than 30 years of experience in the biopharmaceutical industry in the United States, Canada, Europe and Asia, including a nearly 25-year tenure at Merck & Co.
“Dawn is a global biopharmaceutical leader whose addition to the board will strengthen the existing breadth of... |
|12/07/18||Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering|
|SOUTH SAN FRANCISCO, Calif., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced the pricing of its underwritten public offering of its common stock for gross proceeds of approximately $150.0 million, before deducting the underwriting discounts and commissions and other estimated off... |